Loading organizations...
Tripos International develops advanced scientific informatics solutions that empower life science researchers. The company provides a suite of software and services designed to enhance molecular discovery efforts, specifically aiding in the identification and optimization of novel compounds for pharmaceutical and biotechnology applications. Its core offerings focus on computational chemistry, data analysis, and predictive modeling, enabling more efficient and informed decision-making throughout the drug discovery pipeline.
The organization's roots trace back to its origins as a spin-out from Washington University, leveraging early insights into the computational needs of chemical and biological research. While specific founding individuals are not readily detailed, the initial impetus for the company was born from recognizing the growing demand for sophisticated digital tools to accelerate scientific breakthroughs. This foundation in academic research shaped its initial trajectory and technical approach.
Life science researchers, primarily within pharmaceutical companies and academic institutions, constitute Tripos International’s primary customer base. The company aims to equip these scientists with tools that streamline complex processes, reduce research timelines, and ultimately contribute to the development of new therapeutics. Its overarching vision is to remain a critical partner in scientific innovation, helping to advance the understanding of molecular interactions and foster the creation of life-changing medicines.
TriPos has 2 tracked investments across 2 companies. The latest tracked deal is $11.0M Series A in MYCS in March 2017.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2017 | MYCS | $11.0M Series A | — | Project A Ventures, Martin Sinner, Florian Heinemann, UWE Horstmann, Global Founders Capital |
| Nov 11, 2015 | ShopCo Technologies | $2.0M Seed | — | Commerzbank, SeedCapital Dortmund, Silicon Valley Bank |